Haemonetics Corporation (HAE) — Fair Value Analysis

Base-case fair value (P50): $67.25 · Current price: $55.12 · Verdict: Undervalued

The Verdict on HAE

HAEMONETICS CORP (HAE) is currently trading at $55.12, and our Monte Carlo simulations indicate a "Fairly Valued" verdict. These simulations, which model thousands of forward scenarios, point to a median fair value (P50) of $67.25. This suggests a potential upside of +22.0% from the current price. Despite this significant percentage gap to our P50 estimate, the probabilistic distribution of outcomes modelled indicates that HAE is not deeply undervalued nor overtly overvalued at its current $55.12 level. Our assessment factors in a wide range of market conditions and company performance scenarios, contextualizing the current price against the robustness of our simulated fair value.

How HAE stacks up against peers

When evaluating HAEMONETICS CORP (HAE), its "average" quality tier signals that its operational and financial health is generally in line with sector standards. This assessment is a critical input into our Monte Carlo analysis, helping to shape the distribution of fair value outcomes. While the +22.0% potential upside to our median fair value (P50) of $67.25 from the current $55.12 is noteworthy, the "average" quality tier suggests that HAE's underlying business fundamentals are solid but not necessarily exceptional compared to its competitive set. This balance between a decent fair value upside and an "average" quality tier contributes to the overall "Fairly Valued" verdict.

What this means for investors

For investors evaluating HAEMONETICS CORP (HAE), the "Fairly Valued" verdict, coupled with an "average" quality tier, suggests a balanced risk/reward profile at the current $55.12 price point. While our Monte Carlo simulations highlight a substantial +22.0% potential upside to our median fair value of $67.25, the company's average operational and financial health prevents it from being deemed deeply undervalued. Our models encompass both optimistic and pessimistic scenarios, providing a comprehensive view beyond the P50. To gain full access to the granular bear and bull case distributions and track HAE's fair value as new fundamentals are released, sign up for FairCurve.